Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 5, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transfers from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- May 31, 2006: Transfer of 16,661 Ordinary Shares.
- June 1, 2006: Transfer of 4,200 Ordinary Shares.
The Company was advised of these transactions on June 2, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Mr J S Heslop, and Dr M Slaoui—hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Checklist
- Verify the total number of shares transferred under the SmithKline Beecham Employee Share Option Plan 1991 during the reporting period.
- Confirm the specific interests of Directors Dr J-P Garnier, Mr J S Heslop, and Dr M Slaoui in the GSK Trust.
- Review the terms of the GSK Trust to understand the discretionary nature of the beneficiary pool.